Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

KT&G Life Sciences

KT&G Life Sciences
2002 FOUNDED
M&A STATUS
21-30 EMPLOYEES
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of medicines and drugs. The company is researching drugs for treating Cancer, Obesity, Type-2 Diabetes, Liver Disease, MELAS Syndrome, Dry Eye Syndrome, Atopic Dermatitis and other metabolic diseases.

Formerly Known As
Mazence
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • B-1004-6 Digital Empire Building 16
  • Deogyang-daero 1556 beon-gil Yeongtong-gu
  • Suwon-si, Gyeonggi-do 443-702
  • South Korea

+82 000-000-0000

KT&G Life Sciences Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore KT&G Life Sciences‘s full profile, request access.

Request full access to PitchBook

KT&G Life Sciences Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore KT&G Life Sciences‘s full profile, request access.

Request full access to PitchBook